Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00163059 · ClinicalTrials.gov registry record · Phase 2
The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00163059 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 30 participants.
The verdict
NCT00163059, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
To determine if the NMDA antagonist, CP-101,606, is effective for depression
Interventions
- DRUG NMDA Antagonist, CP-101,606 (traxoprodil)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-05 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00163059
The ClinicalTrials.gov registry entry for NCT00163059 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NMDA Antagonist, CP-101,606 (traxoprodil) is the first listed.
NCT00163059 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00163059 about?
NCT00163059 is a clinical study titled "The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD". To determine if the NMDA antagonist, CP-101,606, is effective for depression
What is the current status of trial NCT00163059?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2004-05. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00163059?
The interventions under investigation include: NMDA Antagonist, CP-101,606 (traxoprodil) (DRUG).
Who is sponsoring clinical trial NCT00163059?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.